
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp is advancing its orphan lung pipeline, which is expected to contribute to long-term diversification and growth for the company. The management's focus on enhanced education and marketing strategies is anticipated to improve product uptake, particularly for Afrezza and Tyvaso DPI, which are gaining market share in their respective indications. Furthermore, Tyvaso DPI's potential for robust royalty revenues from the idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) segments presents favorable financial opportunities, driving positive outlooks for the company.
Bears say
MannKind Corp faces a negative outlook primarily due to the vulnerabilities in its intellectual property protections, which could lead to diminished competitive advantages and market share erosion. Additionally, ongoing issues with pricing adjustments for its products suggest challenges in maintaining profitability amid competitive pressures from well-capitalized rivals with established offerings. Delays in regulatory approvals or adverse trial outcomes related to key therapies, such as MNKD-102 and MNKD-201, further exacerbate concerns over future commercialization potential and market opportunities.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares